- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00608634
Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
Phase 2a Randomized, Placebo-Controlled, Double-Blind Trial of Topical Perillyl Alcohol in Sun Damaged Skin
RATIONALE: Drugs used in chemotherapy, such as perillyl alcohol, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing. It is not yet known which dose of topical perillyl alcohol is more effective in stopping the development of cancer in sun damaged skin.
PURPOSE: This randomized phase II trial is studying high-dose topical perillyl alcohol to see how well it works compared with low-dose topical perillyl alcohol in treating patients with sun damaged skin and actinic keratoses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- To determine if topical administration of perillyl alcohol (POH) cream can reverse actinic damage as evidenced by normalization of quantitative skin histopathology scores in skin tissue biopsy samples from patients with moderate to severe sun damage.
Secondary
- To determine if topical POH can be administered safely to the forearms of these patients.
OUTLINE: Patients are randomized to 1 of 3 arms.
- Placebo: Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
- Low Dose: Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
- High Dose: Patients apply POH cream (0.76%) as in arm II. Patients undergo tissue sampling of the right or left dorsal forearm and of physician-selected representative actinic keratoses (AK) at baseline and after completion of study therapy. Tissue samples are assessed for changes in patterns of biomarker expression (i.e., p53, apoptosis, c-Fos histopathology) and karyometry. After completion of study therapy, patients undergo tissue sampling of the opposite forearm as well as blood sample collection to determine perillyl alcohol (POH) levels in blood and biopsy samples. Urine is also collected and analyzed for safety at the end of treatment. Digital photographs of the forearms and hands are obtained at baseline and after 3 months of study treatment. Optical coherence tomography imaging is also performed on pre- and post-biopsy sites to quantify the effect of POH on sun damage and AK in skin.
After completion of study treatment, patients are followed monthly.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724-5024
- Arizona Cancer Center at University of Arizona Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Resident of Pima or adjoining Southern Arizona county
- Patients outside of Pima County are also eligible
Sun damaged skin as judged by the study physician and quantifiable, clinically diagnosed, and visible actinic keratoses (AK) on both dorsal forearms, with at least two AK on each arm
- AK lesions must not be clustered, confluent, or too numerous to count accurately
- Presence of AK on sites other than the test area allowed
- No significant inflammation or irritation of the skin of the upper extremities that is not clinically diagnosed as sun damage or AK
- Patients must agree to limit sun exposure as much as possible and may continue their normal pattern of sunscreen use
PATIENT CHARACTERISTICS:
Inclusion criteria:
- Females must not be of childbearing potential, and therefore must be post-menopausal or surgically sterile by hysterectomy
- Not pregnant or nursing
Exclusion criteria:
Concurrent skin malignancy or disorder of the upper extremities
- Patients with Squamous cell carcinoma or basal cell carcinoma in an area other than the test area are eligible upon excision of the Squamous cell carcinoma or basal cell carcinoma
- Patients who are immunosuppressed by virtue of medication or disease
- Serious concurrent illness that could interfere with study regimen
- Invasive cancer within the past 5 years
PRIOR CONCURRENT THERAPY:
- At least 30 days since prior topical medications to the skin of the upper extremities except for emollients or sunscreens
At least 30 days since prior and no concurrent mega-doses of vitamins, defined as any of the following:
- More than 5 times the recommended daily allowance
- More than 5 capsules of multivitamins
- 400 IU of vitamin E
- 200 μg of selenium
- 1 gm of vitamin C
At least 6 months since prior and no concurrent therapy for squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) anywhere in the test area (i.e., the forearms or hands)
- Treatment for Squamous cell carcinoma or basal cell carcinoma on sites other than the test area is allowed
- At least 4 weeks since prior surgical biopsy, surgical excision, or cryotherapy for AK in the test area and the sites must have healed
- At least 6 months since prior topical treatment (e.g., 5-fluorouracil or imiquimod) for AK
- No concurrent therapy that may interfere with clinical evaluations
- No concurrent topical drug treatment (e.g., retinoids, aminolevulinic acid, diclofenac sodium, imiquimod, or fluorouracil) to any area of skin, including test area
- No concurrent enrollment in another clinical trial
- No concurrent topical citrus peel or consumption of citrus peel
- No chemotherapy for cancer within the past 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
|
Applied as topical cream
|
Experimental: Low Dose POH 0.30%
Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
|
Applied as topical cream
|
Experimental: High Dose POH 0.76%
Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
|
Applied as topical cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Histopathology Score of Sun Damaged Skin by Treatment Group
Time Frame: Baseline to 3 months
|
The histopathologic scoring for skin biopsies from sun-damaged skin to assess the following seven characteristics: 1- atypia (levels 0, 1 & 2), 2- inflammation (grades 0, 1 & 2), 3- hyperkeratosis (loss of basket weave pattern of stratum corneum), 4- parakeratosis (present when there were >3 characteristic nuclei per 40:1 field in stratum corneum), 5- dyskeratosis (focal presence of cells with homogenous, pink cytoplasm n pyknotic nuclei), 6- epidermotropism (lymphocytes migration of >3 cells into epidermis, 7- loss of granular layer.
All assessments were done using a 40:1 objective.
|
Baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Related Events From Perillyl Alcohol at Administered Doses by Participants
Time Frame: 3 months
|
The events do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe.
(NCI)
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Steve Stratton, PhD, University of Arizona
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000582634
- P30CA023074 (U.S. NIH Grant/Contract)
- P01CA027502 (U.S. NIH Grant/Contract)
- UARIZ-HSC-04-27 (Other Identifier: UA IRB no.)
- UARIZ-POH-002 (Other Identifier: NCI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precancerous Condition
-
Xiyuan Hospital of China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing Friendship... and other collaboratorsRecruiting
-
National Cancer Institute (NCI)TerminatedMetaplasia | Dysplasia | Pulmonary Precancerous ConditionUnited States
-
National Cancer Institute (NCI)CompletedNeoplasms | Precancerous ConditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Emory UniversityNational Institutes of Health (NIH)CompletedPrecancerous ConditionsUnited States
-
Renmin Hospital of Wuhan UniversityCompleted
-
All India Institute of Medical Sciences, New DelhiCompletedPrecancerous ConditionsIndia
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States